This study retrospectively reviewed the pathological remission status of NAT for HER2-positive BC and compared the efficacy of HP and HPy targeted therapies combined with chemotherapy, yielding results similar to those of previous studies (27–30). The gene discussed is ERBB2; the disease is breast cancer.